A rapidly spreading strain of H5N1 avian influenza, more commonly referred to as bird flu, has ravaged bird populations worldwide. Since 2022, over 147 million birds in the U.S. alone have been affected, causing economic strain, increasing egg prices, and growing public health concerns. The virus has also begun spreading to other mammals, including dairy cows, cats, and even humans. The question of the day stands tall: what if bird flu mutated to turn airborne and effectively spread among people? Scientists warned that such mutation would be all it took for the next great global pandemic. Understanding Bird Flu: What makes it dangerous?

Bird flu is one of the forms of influenza which mainly infects birds but occasionally jumps to humans and other mammals. The high fatality rate among infected humans makes H5N1 more alarming. Similar to human flu viruses such as H1N1 and H3N2, H5N1 also has distinct protein structures that will not let it spread from one person to another, at least for now.

There are two major known subtypes of avian flu that have infected humans: influenza A(H5N1) and influenza A(H7N9). WHO reports that H5N1 mortality in the Western Pacific Region has reached up to 54% among reported cases. Despite the fact that human infections are rare, health experts are always worried about mutation.

Can Bird Flu Become Airborne?

Currently, H5N1 is not yet able to be transmitted from person to person by the air, although viruses are found to evolve. If H5N1's genetic makeup is changed in such a manner that it can be airborne, scientists fear that it may lead to a deadly pandemic. Unlike seasonal influenza, which spreads by respiratory droplets, bird flu is mainly transmitted by direct contact or any exposure to the infected animal or their body fluids. However, airborne transmission would mean the virus could spread much more easily, making containment significantly more difficult.

Researchers are keeping a close eye on cases in mammals, as transmission among non-bird species may be a sign that the virus is adapting. Pandemics such as the 1918 Spanish flu have, in the past, originated from animal influenza viruses that mutated to become highly transmissible in humans. If H5N1 takes this path, the world may be facing a severe public health crisis.

How Do Humans Get Infected with Bird Flu?

Although it is rare, bird flu can be transmitted to humans. Infected birds spread the virus through their saliva, mucus, and excrement. Other infected animals, like dairy cows, can also harbor the virus in their respiratory secretions, milk, or blood. In these cases, the virus is transferred to humans by direct contact with infected animals or surfaces. These viruses may enter the body through the eyes, nose, or mouth and can be inhaled via airborne particles, such as dust.

Although human infections have been few, the threat remains that each new case increases the possibility of mutation. The Centers for Disease Control and Prevention, U.S. emphasizes that the risk to the general population remains low, but cautions close contact workers who work closely with animals, like farmworkers and veterinarians.

Symptoms and Duration of Bird Flu Infection in Humans

The incubation period for H5N1 in humans varies but generally ranges between 2 to 5 days, with some cases taking up to 17 days to manifest symptoms. Common symptoms include:

• Fever
• Fatigue
• Cough
• Muscle aches
• Sore throat
• Nausea and vomiting
• Diarrhea
• Stuffy or runny nose
• Shortness of breath (dyspnea)
• Pink eye (conjunctivitis)

Most recent U.S. cases have been mildly symptomatic but, worldwide, H5N1 infections have caused severe respiratory illness and sometimes death. Mortality has been high in all previous outbreaks; thus, officials are on their toes in regard to new infections.

Who's at Greatest Risk?

The people at high risk of acquiring bird flu are those who are in close contact with infected animals, such as poultry farm workers, veterinarians, and dairy farmers. Also, people whose immune systems are weakened, including young children and older adults, are more susceptible to severe illness. Although this is rare, there have been documented cases of limited human-to-human transmission, especially among family members caring for infected individuals.

Are Eggs Safe To Eat?

Well, health experts have assured me that properly cooked poultry and eggs do not harbor the virus of avian bird flu. Also, high heat will kill such a virus for human consumption; however, sometimes birds get flu even after ingesting raw commercial pet food leading to the transfer of the diseases in under-cooked animal-based food products.

Raw milk from infected cows remains a potential risk, though more research is needed to determine the extent of its transmissibility. The CDC advises avoiding raw dairy products and ensuring that all poultry and eggs are thoroughly cooked before consumption.

Preventive Measures: How to Stay Safe

Although the current level of risk in humans is quite low, extra precautions are best taken, starting with people regularly in contact with birds or live stocks. Such precautions have included the following recommendation by the CDC:

• Avoid all direct contact with sick or dead birds and animals.
• Use adequate protective equipment- gloves, mask, goggles-as needed to collect potentially infected animals.
• Wash hands well afterwards with soap, water, antiseptic cleaners, and all poultry and its products.
• Poultry and eggs should be cooked to an internal temperature of 165°F/74°C.
• Pasteurized dairy products are the safest options.

Monitor for symptoms if you have been exposed to infected animals. Seek medical attention if flu-like symptoms occur.

The Uncertain Future of H5N1

Although the threat of an airborne mutation is speculative at this point, scientists warn against complacency. Surveillance programs monitor changes in the virus, and vaccine development is ongoing to prepare for a potential outbreak.

Like all other emerging infectious diseases, preparation is essential. Public health officers encourage further studies and collaboration that would ensure an early detection and control of H5N1 before it even threatens the entire world.

For now, the risk of a bird flu pandemic is low, but the experience with COVID-19 teaches that preparedness should be proactive. Understanding the risks, staying informed, and following recommended safety protocols can help to minimize potential dangers in the years ahead.

"God asks no man whether he will accept life. That is not the choice. You must take it. The only choice is how."

This is what Justice JB Pardiwala said, quoting Henry Ward Beecher to allow India's first ever passive euthanasia for Harish Rana. AIIMS Delhi has now started protocols to implement the Supreme Court verdict for Harish Rana's passive euthanasia. Sources and several reports have mentioned that the process could take two to three weeks.

How Is AIIMS Delhi Preparing For Passive Euthanasia?

A specialized team headed by professor and head of the department of anesthesia and palliative medicine, Dr Seema Mishra, has been constituted to implement the process. The team comprises doctors from departments of neurosurgery, onco-anesthesia, and palliative medicine, and psychiatry.

“The process generally involves withholding or withdrawing the nutritional support gradually while ensuring adequate pain relief. The patient is given palliative sedation so that he or she is not in distress. Life support measures such as artificial nutrition, oxygen and medications are slowly withdrawn. The aim is not to prolong nor hasten death,” Dr Sushma Bhatnagar, former head of the department of onco-anaesthesia, pain and palliative care, AIIMS-Delhi.

Harish Rana Update

A video from Rana's home in Ghaziabad showed that relatives were offering prayers and a member of the Brahma Kumaris put a 'tilak' on his forehead. She said, "Sabko maaf karte hue, sabse maafi mange hue, so jaao...theek hai." Which loosely translates to: Forgiving everyone and asking forgiveness from everyone. Now sleep. It's okay.

The Brahma Kumari seen in the video was Sister Lovely from Mohan Nagar Seva Kendra in Ghaziabad. Komal, who is also a member of Brahma Kumaris based in Mount Abu, told this to news agency Press Trust of India (PTI). "She is following a ritual with the words that mean he (Harish) leave the world in a happy state, seeking and giving forgiveness...it is part of a meditative chant that comforts the soul and eases the entire process of soul merging with the sublime," she told PTI.

According to Komal, alongside medical consultations, the family also sought spiritual guidance as they prepared for the inevitable after the Supreme Court’s directions.

Read: Harish Rana Case Brings Spotlight On How Passive Euthanasia Has Evolved Over The Years

Harish Rana's Passive Euthanasia

The Supreme Court of India, in a landmark judgment allowed 32-year-old Harish Rana, who had been living in a vegetative state for last 13 years, the right to die. This means, that the apex court allowed passive euthanasia for Rana. The bench comprising Justice JB Pardiwala an Justice KV Vishwanathan allowed the withdrawal of life support of Rana, who has been in a coma and kept alive on tubes for breathing and nutrition after he sustained severe head injuries following a fall from a building in 2013 in Chandigarh.

The judgment is a win, however, Ashok, Rana's father said that his feelings are mixed. "As a father, this is extremely painful. But on humanitarian grounds, this is the best we can do for my son." He continued, "It is just not a matter of my son, but there are many others in such a state in the country. I think it is the grace of God who guided the Supreme Court judges... I am happy that with this judgments, many others may find a way."

Tech giant Microsoft's new artificial intelligence model GigaTIME will help reduce time and cost as well as expand access to cancer care, said CEO Satya Nadella today.

Nadella noted that its multimodal AI system has shown promise in transforming routine pathology slides into detailed spatial proteomics data -- a high-resolution map of proteins.

The advanced technology may help doctors analyze tumors faster, thus bringing hope to millions of cancer patients worldwide for a better and faster diagnosis.

Taking to social media platform X, Nadella said: “We’ve trained a multimodal AI model to turn routine pathology slides into spatial proteomics, with the potential to reduce time and cost while expanding access to cancer care”.

What is GigaTIME

GigaTIME is a multimodal AI model for translating routinely available hematoxylin and eosin (H&E) pathology slides to virtual multiplex immunofluorescence (mIF) images.

H&E is the "gold standard" technique in pathology for diagnosing cancer. The mIF images share details of proteins and their locations in cancer cells, thus advancing precision immuno-oncology research.

Developed in collaboration with Providence and the University of Washington, the team trained GigaTIME on a dataset of 40 million cells with paired H&E and mIF images across 21 protein channels.

The multimodal AI, which analyzed standard pathology slides, showed the potential to generate a “virtual population” of tumor cells. It also revealed the detailed protein activity within cancer cells.

The images also offer deeper insights into how tumors behave and disease progression, enabling doctors to cut down the time and cost of diagnosis.

“GigaTIME is about unlocking insights that were previously out of reach,” explained Carlo Bifulco, chief medical officer of Providence Genomics and medical director of cancer genomics and precision oncology at the Providence Cancer Institute, in a Microsoft Blogpost

“By analyzing the tumor microenvironment of thousands of patients, GigaTIME has the potential to accelerate discoveries that will shape the future of precision oncology and improve patient outcomes,” Bifulco added.

How GigaTIME Works

In the paper, detailed in the journal Cell, scientists from Microsoft reported that they applied GigaTIME to 14,256 cancer patients from 51 hospitals and over a thousand clinics.

The AI system generated a virtual population of around 300,000 mIF images spanning 24 cancer types and 306 cancer subtypes.

This virtual population uncovered 1,234 statistically significant associations linking mIF protein activations with key clinical attributes such as biomarkers, staging, and patient survival.

"By translating readily available H&E pathology slides into high-resolution virtual mIF data, GigaTIME provides a novel research framework for exploring precision immuno-oncology through population-scale TIME analysis and discovery," the researchers said.

"The GigaTIME model is publicly available to help accelerate clinical research in precision oncology," they added.

The American College of Cardiology (ACC) and the American Heart Association (AHA) released the 2026 ACC/AHA Guideline on the Management of Dyslipidemia. These guidelines introduce important updates in cardiovascular risk assessment, lipid testing, and lipid-lowering therapy.

The guidelines focus on the cases of young people facing heart issues and thus highlight 10 key actions for 2026, which also includes early detection and starting cholesterol check as early as the age 19.

The guidelines have been published in the March 2026 issue of Circulation. The document was developed by a multidisciplinary panel that presented several organization, including the American Diabetes Association (ADA), National Lipid Association (NLA), and Preventative Cardiovascular Nurses Association (PCNA).

The 2026 guidelines will replace the widely used earlier AHA/ACC 2018 cholesterol guidelines, while incorporate new findings and big clinical trials, which will include lipid biomarkers, and enhanced cardiovascular risk prediction models.

What Are The New Steps Introduced By ACC/AHA 2026 Guidelines?

The focus of the new guidelines is on early detection and lifelong risk reduction. The key 10 actions include:

Read: AHA Cholesterol Guidelines 2026: How Indians Can Improve Heart Health

Early Prevention

One of the biggest shifts in the new recommendations is the focus on early detection and management of lipid disorders, especially among younger people. The aim is to reduce lifetime exposure to atherogenic lipoproteins and prevent the long-term development of atherosclerotic cardiovascular disease (ASCVD).

Use PREVENT For Risk Prediction

The guidelines introduce the PREVENT risk equations to estimate 10-year and 30-year cardiovascular risk in adults aged 30–79. This replaces the earlier pooled cohort equations and is expected to improve how patients are categorized according to risk.

Early Treatment For Borderline-risk Patients

Lipid-lowering therapy can now be considered for primary prevention in individuals with a borderline 10-year ASCVD risk (3–5%). For those with intermediate risk (5–10%), treatment decisions should involve shared discussions between doctors and patients.

LDL-C

The updated guideline reintroduces clear LDL-C and non-HDL-C treatment targets, along with percentage reduction goals. These benchmarks help clinicians decide when to intensify treatment.

ApOB Testing

The recommendations suggest measuring apolipoprotein B (ApoB), particularly in patients with high triglycerides, diabetes, or cases where LDL-C levels may underestimate the number of atherogenic particles.

Adults Must Undergo One-time Lp(a) Testing

Because lipoprotein(a) [Lp(a)] is a genetic risk factor for cardiovascular disease, the guideline advises that all adults undergo at least one lifetime test to identify inherited cardiovascular risk.

Coronary Calcium Scoring (CAC)

Coronary artery calcium (CAC) scoring can help guide treatment decisions, especially for people with borderline or intermediate cardiovascular risk who are unsure about starting statin therapy.

Lipid Therapy for High Risk Comorbidities

Adults aged 40–75 years with conditions such as diabetes, stage 3–4 chronic kidney disease, or HIV infection should receive lipid-lowering therapy for primary prevention, even if their baseline LDL-C levels are not elevated.

Secondary Prevention Methods

For patients with established ASCVD and high risk, the guideline recommends an LDL-C target below 55 mg/dL, as lower levels are linked to better cardiovascular protection.

Stating - The Cornerstone of Therapy

Despite newer medications, statins continue to be the first-line therapy for most patients with dyslipidemia and play a major role in reducing ASCVD risk. Additional treatments such as ezetimibe, PCSK9 inhibitors, bempedoic acid, and inclisiran may be added depending on treatment goals and patient needs.